Jove
Visualize
联系我们
JoVE
x logofacebook logolinkedin logoyoutube logo
关于 JoVE
概览领导团队博客JoVE 帮助中心
作者
出版流程编辑委员会范围与政策同行评审常见问题投稿
图书馆员
用户评价订阅访问资源图书馆顾问委员会常见问题
研究
JoVE JournalMethods CollectionsJoVE Encyclopedia of Experiments存档
教育
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab Manual教师资源中心教师网站
使用条款与条件
隐私政策
政策

相关概念视频

Heart Failure VI: Adjunct Therapies01:22

Heart Failure VI: Adjunct Therapies

16
Additional therapies for treating patients with heart failure (HF) may include procedural interventions, supplemental oxygen, the management of sleep disorders, and nutritional therapy.Procedural InterventionsImplantable Cardioverter-Defibrillator: For patients at risk of life-threatening arrhythmias due to severe left ventricular dysfunction, an Implantable Cardioverter-Defibrillator (ICD) can detect and terminate these arrhythmias, preventing sudden cardiac death and improving survival rates.
16
Heart Failure V: Medical Management01:30

Heart Failure V: Medical Management

13
Medical Management of Acute Decompensated Heart Failure (ADHF)The primary goals of therapy for patients hospitalized with acute decompensated heart failure (ADHF) include:Relieving symptomsOptimizing volume statusSupporting oxygenation and ventilationMaintaining cardiac output (CO) and end-organ perfusionIdentifying and addressing the cause of ADHFPreventing complicationsProviding patient education on factors precipitating HF exacerbationPlanning for dischargeOngoing monitoring and assessment...
13
Heart Failure VII: Nursing Interventions01:30

Heart Failure VII: Nursing Interventions

94
The first step in nursing management of a patient with heart failure involves thoroughly assessing the patient's medical history.Subjective Data: Obtain the patient's medical history of coronary artery disease, hypertension, myocardial infarction, and symptoms like dyspnea, orthopnea, and paroxysmal nocturnal dyspnea.Objective Data: Conduct a physical examination to identify findings such as jugular vein distention, pulmonary crackles, tachycardia, murmurs, peripheral edema, and vital signs,...
94
Heart Failure Drugs: Inhibitors of Renin-Angiotensin System01:26

Heart Failure Drugs: Inhibitors of Renin-Angiotensin System

463
The activation of the sympathetic nervous system and the renin-angiotensin-aldosterone system (RAAS) contributes to cardiac remodeling, and inhibiting the RAAS is a pharmacological target in heart failure management. As a result, neurohumoral modulation is a crucial treatment principle for managing heart failure. This approach involves using medications like ACE inhibitors (ACEIs), angiotensin receptor blockers (ARBs), β-blockers, mineralocorticoid receptor antagonists (MRAs), and neutral...
463
Cardiomyopathy V: Interprofessional Care01:29

Cardiomyopathy V: Interprofessional Care

16
Managing cardiomyopathy involves addressing underlying or precipitating causes, treating heart failure with medications, and implementing dietary changes and a balanced exercise and rest regimen.Lifestyle ModificationsCardiomyopathy patients should adopt a low-sodium diet to reduce fluid retention and manage heart failure. A personalized exercise and rest plan helps maintain physical fitness without overstraining the heart. Avoiding alcohol and tobacco is essential to prevent further damage to...
16
Heart Failure Drugs: Inotropic Agents01:26

Heart Failure Drugs: Inotropic Agents

621
Positive inotropic agents are commonly used as the first line of treatment for heart failure. One such agent is digoxin, derived from the genus Digitalis, which has been known for centuries but effectively utilized since 1785. However, these cardiac glycosides can have potentially toxic effects due to their mechanism of action, which involves inhibiting Na+/K+-ATPase and increasing contractility. Digoxin is absorbed orally and distributed in various tissues, including the CNS. It has a long...
621

您也可能阅读

相关文章

通过共同作者、期刊和引用图与本文相关的文章。

排序
Same author

Right Ventricular Metrics as End Points in Clinical Trials: A Review.

JAMA cardiology·2026
Same author

Comprehensive Clinical Benefit of CCM in HFrEF Patients - a win-ratio analysis of FIX-HF-5C randomized trial.

ESC heart failure·2026
Same author

Universal Pulmonary Resistance-Compliance Relationship: And Why It Matters?

Circulation. Heart failure·2026
Same author

De Novo Aortic Insufficiency and Its Progression in Patients on Microaxial Flow Pump Support Before Durable Left Ventricular Assist Device.

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same author

Cardiac microcurrent therapy in heart failure: Mechanistic rationale, early clinical evidence, and future directions.

Heart failure reviews·2026
Same author

Does Pacemaker Mode Affect Outcomes in Patients With HeartMate 3 LVAD?

ASAIO journal (American Society for Artificial Internal Organs : 1992)·2026
Same journal

REVEALing New Standards: Low Risk Redefined.

JACC. Heart failure·2026
Same journal

Implantable Cardioverter-Defibrillator Therapy in Contemporary Heart Failure Patients: An Analysis From the EMPEROR-Reduced Trial.

JACC. Heart failure·2026
Same journal

Sodium-Glucose Cotransporter 2 Inhibitor Following Left Ventricular Assist Device Implantation: A Randomized Controlled Trial.

JACC. Heart failure·2026
Same journal

Noninvasive Wearable-Based Algorithm to Predict Worsening Heart Failure by Change in Natriuretic Peptide Levels.

JACC. Heart failure·2026
Same journal

Long-Term HM3 Outcomes: Is Age the Signal or the Surrogate?

JACC. Heart failure·2026
Same journal

Impact of Age on Long-Term Clinical Outcomes Following HeartMate 3 LVAD Implantation: Insights From the MOMENTUM 3 Trial.

JACC. Heart failure·2026
查看所有相关文章

相关实验视频

Updated: Jul 18, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K

对于心力衰竭的设备干预

Husam M Salah1, Marat Fudim2, Daniel Burkhoff3

  • 1Department of Internal Medicine, University of Arkansas for Medical Sciences, Little Rock, Arkansas, USA.

JACC. Heart failure
|August 23, 2023
PubMed
概括
此摘要是机器生成的。

基于新型设备的干预措施为心力衰竭 (HF) 患者提供了新的希望,尽管最佳药物治疗仍然存在症状. 这些先进疗法解决了各种HF表型的目前治疗方法的未满足需求和局限性.

关键词:
在GDMTT的GDMT.设备干预 设备干预医疗器械治疗的设备治疗心脏衰竭是因为心脏衰竭.干预性心力衰竭是干预性心力衰竭.

更多相关视频

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

相关实验视频

Last Updated: Jul 18, 2025

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction
09:20

Lumped-Parameter and Finite Element Modeling of Heart Failure with Preserved Ejection Fraction

Published on: February 13, 2021

6.5K
Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock
06:10

Utilizing Percutaneous Ventricular Assist Devices in Acute Myocardial Infarction Complicated by Cardiogenic Shock

Published on: June 12, 2021

3.3K
Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock
07:39

Use of a Percutaneous Ventricular Assist Device/Left Atrium to Femoral Artery Bypass System for Cardiogenic Shock

Published on: August 16, 2021

3.6K

科学领域:

  • 心脏病学 心脏病学
  • 生物医学工程 生物医学工程
  • 医疗器械 医疗器械

背景情况:

  • 尽管药物治疗方面取得了进展,但心力衰竭 (HF) 继续导致显著的发病率,死亡率和住院病例.
  • 许多HF患者即使在最佳的医疗管理下仍然表现出症状,突出显示出未满足的临床需求.

研究的目的:

  • 审查心力衰竭 (HF) 基于设备的干预措施的不断变化的格局.
  • 突出这些新型疗法在当前高频管理工作流程中实施的关键考虑因素.

主要方法:

  • 审查当前关于基于HF的设备干预的文献.
  • 分析设备疗法的优势,而不是药物疗法.
  • 讨论实施挑战和工作流集成.

主要成果:

  • 新型基于设备的干预正在成为各种HF表型的有前途的治疗选择.
  • 这些设备可以克服药物治疗的局限性,包括坚持问题和不一致的输送.
  • 设备干预可能比单独使用药物更有效地针对HF病理生理学.

结论:

  • 基于设备的干预措施在治疗心力衰竭方面取得了重大进展.
  • 成功融入临床实践需要仔细考虑工作流程和实施策略.
  • 这些疗法有可能改善广泛的HF患者的治疗结果.